NO/cGMP: The past, the present, and the future

Methods in Molecular Biology

Volumn 1020, Issue , 2013, Pages 1-16

  Russwurm, Michael ^a   Russwurm, Corina ^a   Koesling, Doris ^a   Mergia, Evanthia ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Cyclic guanosine monophosphate; Guanylyl cyclase; Hyperpolarization activated cyclic nucleotide gated channels; Nitric oxide; Phosphodiesterases; Synaptic plasticity; Vasorelaxation

Indexed keywords

ALDOSTERONE; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE 1; GLUTAMIC ACID; GUANOSINE TRIPHOSPHATE; GUANYLATE CYCLASE; HISTIDINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NITRIC OXIDE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE VI;

AMINO ACID SEQUENCE; ARTICLE; CENTRAL NERVOUS SYSTEM; CORPUS CAVERNOSUM; DNA BASE COMPOSITION; DNA MODIFICATION; HEART MUSCLE CONTRACTILITY; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE PRESSURE; HIPPOCAMPAL CA1 REGION; LONG TERM POTENTIATION; MOLECULAR WEIGHT; NEUROTRANSMITTER RELEASE; NONADRENERGIC NONCHOLINERGIC NERVE; NONHUMAN; PENIS ERECTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PULMONARY HYPERTENSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SEQUENCE HOMOLOGY; SMOOTH MUSCLE RELAXATION; SYNAPTIC MEMBRANE; SYNAPTIC TRANSMISSION; THROMBOCYTE AGGREGATION; VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE;

MUS;

EID: 84883185689     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-459-3_1     Document Type: Article

References (78)

1. Schultz G, Böhme E, Munske K (1969) Guanyl cyclase. Determination of enzyme activity. Life Sci 8:1323-1332
2. Chrisman TD, Garbers DL, Parks MA, Hardman JG (1975) Characterization of particulate and soluble guanylate cyclases from rat lung. J Biol Chem 250:374-381
3. Palmer RMJ, Ferrige AG, Moncada S (1987) Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327:524-526
4. Kuno T, Andresen JW, Kamisaki Y, Waldman SA, Chang LY, Saheki S, Leitman DC, Nakane M, Murad F (1986) Co-purification of an atrial natriuretic factor receptor and particulate guanylate cyclase from rat lung. J Biol Chem 261: 5817-5823
5. Kuhn M (2009) Function and dysfunction of mammalian membrane guanylyl cyclase receptors: Lessons from genetic mouse models and implications for human diseases. Handb Exp Pharmacol 191:47-69
6. Arnold WP, Mittal CK, Katsuki S, Murad F (1977) Nitric oxide activates guanylate cyclase and increases guanosine 3':5'-cyclic monophosphate levels in various tissue preparations. Proc Natl Acad Sci USA 74:3203-3207
7. Hofmann F, Wegener JW (2013) cGMP dependent protein kinases (cGK). Methods Mol Biol
8. Gerzer R, Hofmann F, Schultz G (1981) Purification of a soluble, sodium-nitroprusside-stimulated guanylate cyclase from bovine lung. Eur J Biochem 116:479-486
9. Kamisaki Y, Saheki S, Nakane M, Palmieri JA, Kuno T, Chang BY, Waldman SA, Murad F (1986) Soluble guanylate cyclase from rat lung exists as a heterodimer. J Biol Chem 261: 7236-7241
10. Gerzer R, Böhme E, Hofmann F, Schultz G (1981) Soluble guanylate cyclase purifi ed from bovine lung contains heme and copper. FEBS Lett 132:71-74
11. Russwurm M, Behrends S, Harteneck C, Koesling D (1998) Functional properties of a naturally occurring isoform of soluble guanylyl cyclase. Biochem J 335:125-130
12. Russwurm M, Wittau N, Koesling D (2001) Guanylyl cyclase/PSD-95 interaction: Targeting of the nitric oxide-sensitive alpha2beta1 guanylyl cyclase to synaptic membranes. J Biol Chem 276:44647-44652
13. Mergia E, Russwurm M, Zoidl G, Koesling D (2003) Major occurrence of the new alpha2bbeta1 isoform of NO-sensitive guanylyl cyclase in brain. Cell Signal 15:189-195
14. Stone JR, Marletta MA (1994) Soluble guanylate cyclase from bovine lung: Activation with nitric oxide and carbon monoxide and spectral characterization of the ferrous and ferric states. Biochemistry 33:36-5640
15. Russwurm M, Koesling D (2004) NO activation of guanylyl cyclase. EMBO J 23: 4443-4450
16. Fernhoff NB, Derbyshire ER, Marletta MA (2009) A nitric oxide/cysteine interaction mediates the activation of soluble guanylate cyclase. Proc Natl Acad Sci USA 106: 21602-21607
17. Schmidt HHHW, Schmidt PM, Stasch J-P (2009) NO- and haem-independent soluble guanylate cyclase activators. Handb Exp Pharmacol 191:309-339
18. Stasch J-P, Hobbs AJ (2009) NO-independent, haem-dependent soluble guanylate cyclase stimulators. Handb Exp Pharmacol 191:277-308
19. Russwurm M, Mergia E, Mullershausen F, Koesling D (2002) Inhibition of deactivation of NO-sensitive guanylyl cyclase accounts for the sensitizing effect of YC-1. J Biol Chem 277:24883-24888
20. Schmidt PM, Stasch JP (2013) Receptor binding assay for NO-independent activators of soluble guanylate cyclase. Methods Mol Biol
21. Acin-Perez R, Russwurm M, Günnewig K, Gertz M, Zoidl G, Ramos L, Buck J, Levin LR, Rassow J, Manfredi G, Steegborn C (2011) A phosphodiesterase 2A isoform localized to mitochondria regulates respiration. J Biol Chem 286:30423-30432
22. Russwurm C, Zoidl G, Koesling D, Russwurm M (2009) Dual acylation of PDE2A splice variant 3: Targeting to synaptic membranes. J Biol Chem 284:25782-25790
23. Jäger R, Russwurm C, Schwede F, Genieser HG, Koesling D, Russwurm M (2012) Activation of PDE10 and PDE11 phosphodiesterases. J Biol Chem 287:1210-1219
24. Jäger R, Groneberg D, Lies B, Bettaga N, Kümmel M, Friebe A (2013) Radioimmunoassay for the quanti fication of cGMP levels in cells and tissues. Methods Mol Biol
25. Mullershausen F, Russwurm M, Thompson WJ, Liu L, Koesling D, Friebe A (2001) Rapid nitric oxide-induced desensitization of the cGMP response is caused by increased activity of phosphodiesterase type 5 paralleled by phosphorylation of the enzyme. J Cell Biol 155:271-278
26. Mullershausen F, Lange A, Mergia E, Friebe A, Koesling D (2006) Desensitization of NO/cGMP signaling in smooth muscle: Blood vessels versus airways. Mol Pharmacol 69:1969-1974
27. Hagiwara M, Endo T, Hidaka H (1984) Effects of vinpocetine on cyclic nucleotide metabolism in vascular smooth muscle. Biochem Pharmacol 33:453-457
28. Rybalkin SD, Rybalkina IG, Shimizu-Albergine M, Tang XB, Beavo JA (2003) PDE5 is converted to an activated state upon cGMP binding to the GAF A domain. EMBO J 22:469-478
29. Mullershausen F, Friebe A, Feil R, Thompson WJ, Hofmann F, Koesling D (2003) Direct activation of PDE5 by cGMP: Long-term effects within NO/cGMP signaling. J Cell Biol 160:719-727
30. Jäger R, Schwede F, Genieser HG, Koesling D, Russwurm M (2010) Activation of PDE2 and PDE5 by specific GAF ligands: Delayed activation of PDE5. Br J Pharmacol 161:1645-1660
31. Turko IV, Francis SH, Corbin JD (1998) Binding of cGMP to both allosteric sites of cGMP-binding cGMP-specific phosphodiesterase (PDE5) is required for its phosphorylation. Biochem J 329:505-510
32. Turko IV, Ballard SA, Francis SH, Corbin JD (1999) Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds. Mol Pharmacol 56:124-130
33. Mullershausen F, Russwurm M, Koesling D, Friebe A (2003) The enhanced NO-induced cGMP response induced by long-term L -NAME treatment is not due to enhanced expression of NO-sensitive guanylyl cyclase. Vascul Pharmacol 40:161-165
34. Friebe A, Mergia E, Dangel O, Lange A, Koesling D (2007) Fatal gastrointestinal obstruction and hypertension in mice lacking nitric oxide-sensitive guanylyl cyclase. Proc Natl Acad Sci USA 104:7699-7704
35. Mergia E, Friebe A, Dangel O, Russwurm M, Koesling D (2006) Spare guanylyl cyclase NO receptors ensure high NO sensitivity in the vascular system. J Clin Invest 116:1731-1737
36. Buys ES, Sips P, Vermeersch P, Raher MJ, Rogge E, Ichinose F, Dewerchin M, Bloch KD, Janssens S, Brouckaert P (2008) Genderspecific hypertension and responsiveness to nitric oxide in sGC alpha1 knockout mice. Cardiovasc Res 79:179-186
37. Pfeifer A, Klatt P, Massberg S, Ny L, Sausbier M, Hirneiss C, Wang GX, Korth M, Aszódi A, Andersson KE, Krombach F, Mayerhofer A, Ruth P, Fässler R, Hofmann F (1998) Defective smooth muscle regulation in cGMP kinase I-deficient mice. EMBO J 17:3045-3051
38. Wagner C, Russwurm M, Jäger R, Friebe A, Koesling D (2005) Dimerization of nitric oxide-sensitive guanylyl cyclase requires the alpha 1 N terminus. J Biol Chem 280: 17687-17693
39. Rees DD, Palmer RM, Moncada S (1989) Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci USA 86:3375-3378
40. Buys ES, Raher MJ, Kirby A, Mohd S, Baron DM, Hayton SR, Tainsh LT, Sips PY, Rauwerdink KM, Yan Q, Tainsh RE, Shakartzi HR, Stevens C, Decaluwé K, Rodrigues-Machado Mda G, Malhotra R, Van de Voorde J, Wang T, Brouckaert P, Daly MJ, Bloch KD (2012) Genetic modifiers of hypertension in soluble guanylate cyclase a 1-deficient mice. J Clin Invest 122:2316-2325
41. van Vliet BN, Chafe LL, Montani JP (2003) Characteristics of 24 h telemetered blood pressure in eNOS-knockout and C57Bl/6 J control mice. J Physiol 549:313-325
42. Vermeersch P, Buys E, Pokreisz P, Marsboom G, Ichinose F, Sips P, Pellens M, Gillijns H, Swinnen M, Graveline A, Collen D, Dewerchin M, Brouckaert P, Bloch KD, Janssens S (2007) Soluble guanylate cyclase-alpha1 deficiency selectively inhibits the pulmonary vasodilator response to nitric oxide and increases the pulmonary vascular remodeling response to chronic hypoxia. Circulation 116:936-943
43. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, Fishman MC (1995) Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 377:239-242
44. Chataigneau T, Félétou M, Huang PL, Fishman MC, Duhault J, Vanhoutte PM (1999) Acetylcholine-induced relaxation in blood vessels from endothelial nitric oxide synthase knockout mice. Br J Pharmacol 126:219-226
45. Rich TC, Britain AL, Stedman T, Leavesley SJ (2013) Hyperspectral imaging of FRET-based cGMP probes. Methods Mol Biol
46. Thunemann M, Fomin N, Krawutschke C, Russwurm M, Feil R (2013) Visualization of cGMP with cGi biosensors. Methods Mol Biol
47. Götz KR, Nikolaev VO (2013) Advances and techniques to measure cGMP in intact cardiomyocytes. Methods Mol Biol
48. Held KF, Dostmann WR (2013) Real-time monitoring the spatio-temporal dynamics of intracellular cGMP in vascular smooth muscle cells. Methods Mol Biol
49. Andersson KE, Wagner G (1995) Physiology of penile erection. Physiol Rev 75:191-236
50. Musicki B, Burnett AL (2006) eNOS function and dysfunction in the penis. Exp Biol Med (Maywood) 231:154-165
51. Nimmegeers S, Sips P, Buys E, Decaluwé K, Brouckaert P, Van de Voorde J (2007) Role of the soluble guanylyl cyclase alpha(1)-subunit in mice corpus cavernosum smooth muscle relaxation. Int J Impot Res 20:278-284
52. Vanneste G, Dhaese I, Sips P, Buys E, Brouckaert P, Lefebvre RA (2007) Gastric motility in soluble guanylate cyclase alpha 1 knock-out mice. J Physiol 584:907-920
53. Ny L, Pfeifer A, Aszòdi A, Ahmad M, Alm P, Hedlund P, Fässler R, Andersson KE (2000) Impaired relaxation of stomach smooth muscle in mice lacking cyclic GMP-dependent protein kinase I. Br J Pharmacol 129:395-401
54. Huang PL, Dawson TM, Bredt DS, Snyder SH, Fishman MC (1993) Targeted disruption of the neuronal nitric oxide synthase gene. Cell 75:1273-1286
55. Morishita T, Tsutsui M, Shimokawa H, Sabanai K, Tasaki H, Suda O, Nakata S, Tanimoto A, Wang KY, Ueta Y, Sasaguri Y, Nakashima Y, Yanagihara N (2005) Nephrogenic diabetes insipidus in mice lacking all nitric oxide synthase isoforms. Proc Natl Acad Sci USA 102:10616-10621
56. Groneberg D, König P, Koesling D, Friebe A (2011) Nitric oxide-sensitive guanylyl cyclase is dispensable for nitrergic signaling and gut motility in mouse intestinal smooth muscle. Gastroenterology 140:1608-1617
57. Ichinose F, Roberts JD Jr, Zapol WM (2004) Inhaled nitric oxide: A selective pulmonary vasodilator: Current uses and therapeutic potential. Circulation 109:3106-3111
58. Steudel W, Scherrer-Crosbie M, Bloch KD, Weimann J, Huang PL, Jones RC, Picard MH, Zapol WM (1998) Sustained pulmonary hypertension and right ventricular hypertrophy after chronic hypoxia in mice with congenital deficiency of nitric oxide synthase 3. J Clin Invest 101:2468-2477
59. Moncada S, Radomski MW, Palmer RM (1998) Endothelium-derived relaxing factor. Identi fication as nitric oxide and role in the control of vascular tone and platelet function. Biochem Pharmacol 37:2495-2501
60. Wanstall JC, Homer KL, Doggrell SA (2005) Evidence for, and importance of, cGMP-independent mechanisms with NO and NO donors on blood vessels and platelets. Curr Vasc Pharmacol 3:41-53
61. Crane MS, Rossi AG, Megson IL (2005) A potential role for extracellular nitric oxide generation in cGMP-independent inhibition of human platelet aggregation: Biochemical and pharmacological considerations. Br J Pharmacol 144:849-859
62. Massberg S, Sausbier M, Klatt P, Bauer M, Pfeifer A, Siess W, Fässler R, Ruth P, Krombach F, Hofmann F (1999) Increased adhesion and aggregation of platelets lacking cyclic guanosine 3 ¢, 5 ¢ -monophosphate kinase I. J Exp Med 189:1255-1264
63. Antl M, von Brühl ML, Eiglsperger C, Werner M, Konrad I, Kocher T, Wilm M, Hofmann F, Massberg S, Schlossmann J (2007) IRAG mediates NO/cGMP-dependent inhibition of platelet aggregation and thrombus formation. Blood 109:552-559
64. Schmidtko A, Gao W, König P, Heine S, Motterlini R, Ruth P, Schlossmann J, Koesling D, Niederberger E, Tegeder I, Friebe A, Geisslinger G (2008) cGMP produced by NO-sensitive guanylyl cyclase essentially contributes to in fl ammatory and neuropathic pain by using targets different from cGMP-dependent protein kinase I. J Neurosci 28:8568-8576
65. Lu R, Schmidtko A (2013) Direct Intrathecal drug delivery in mice for detecting in vivo effects of cGMP on pain processing. Methods Mol Biol
66. Snyder SH, Bredt DS (1991) Nitric oxide as a neuronal messenger. Trends Pharmacol Sci 12:125-128
67. Boehning D, Snyder SH (2003) Novel neural modulators. Annu Rev Neurosci 26:105-131
68. Garthwaite J (2008) Concepts of neural nitric oxide-mediated transmission. Eur J Neurosci 27:2783-2802
69. Christopherson KS, Hillier BJ, Lim WA, Bredt DS (1999) PSD-95 assembles a ternary complex with the N-methyl- D -aspartic acid receptor and a bivalent neuronal NO synthase PDZ domain. J Biol Chem 274:27467-27473
70. Garthwaite J, Charles SL, Chess-Williams R (1988) Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain. Nature 336:385-388
71. O'Dell TJ, Hawkins RD, Kandel ER, Arancio O (1991) Tests of the roles of two diffusible substances in long-term potentiation: Evidence for nitric oxide as a possible early retrograde messenger. Proc Natl Acad Sci USA 88:11285-11289
72. Schuman EM, Madison DV (1991) A requirement for the intercellular messenger nitric oxide in long-term potentiation. Science 254:1503-1506
73. Taqatqeh F, Mergia E, Neitz A, Eysel UT, Koesling D, Mittmann T (2009) More than a retrograde messenger: Nitric oxide needs two cGMP pathways to induce hippocampal longterm potentiation. J Neurosci 29:9344-9350
74. Haghikia A, Mergia E, Friebe A, Eysel UT, Koesling D, Mittmann T (2007) Long-term potentiation in the visual cortex requires both nitric oxide receptor guanylyl cyclases. J Neurosci 27:818-823
75. Bon CL, Garthwaite J (2003) On the role of nitric oxide in hippocampal long-term potentiation. J Neurosci 23:1941-1948
76. Hopper RA, Garthwaite J (2006) Tonic and phasic nitric oxide signals in signals in hippocampal long-term potentiation. J Neurosci 26:11513-11521
77. Son H, Hawkins RD, Martin K, Kiebler M, Huang PL, Fishman MC, Kandel ER (1996) Long-term potentiation is reduced in mice that are doubly mutant in endothelial and neuronal nitric oxide synthase. Cell 13: 1015-1023
78. Neitz A, Mergia E, Eysel UT, Koesling D, Mittmann T (2011) NO/cGMP facilitates glutamate release via HCN channels. Eur J Neurosci 33:1611-1621